
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

39234773
CN-22-2016
10.2174/1570159X22666240130091235
Medicine, Neurology, Pharmacology, Neuroscience
Glymphatic System and Psychiatric Disorders: A Rapid Comprehensive Scoping Review
Barlattani Tommaso 1
Grandinetti Paolo 2
Di Cintio Alexsander 1
Montemagno Alessio 1
Testa Roberta 2
D’Amelio Chiara 1
Olivieri Luigi 2
Tomasetti Carmine 2
Rossi Alessandro 1
Pacitti Francesca 1*
De Berardis Domenico 2
1 Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, Via Vetoio, Coppito, 67100 L’Aquila, Italy;
2 National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital G. Mazzini, ASL 4 Teramo, Italy
* Address correspondence to this author at the Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, Via Vetoio, Coppito, 67100 L’Aquila, Italy; E-mail: francesca.pacitti@univaq.it
31 1 2024
2024
22 12 20162033
29 5 2023
22 7 2023
25 8 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Background

Since discovering the glymphatic system, there has been a looming interest in exploring its relationship with psychiatric disorders. Recently, increasing evidence suggests an involvement of the glymphatic system in the pathophysiology of psychiatric disorders. However, clear data are still lacking. In this context, this rapid comprehensive PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) scoping review aims to identify and analyze current evidence about the relation between the glymphatic system and psychiatric disorders.

Methods

We conducted a comprehensive review of the literature and then proceeded to discuss the findings narratively. Tables were then constructed and articles were sorted according to authors, year, title, location of study, sample size, psychiatric disorder, the aim of the study, principal findings, implications.

Results

Twenty papers were identified as eligible, among which 2 articles on Schizophrenia, 1 on Autism Spectrum Disorders, 2 on Depression, 1 on Depression and Trauma-related Disorders, 1 on Depression and Anxiety, 2 on Anxiety and Sleep Disorders, 8 on Sleep Disorders, 2 on Alcohol use disorder and 1 on Cocaine Use Disorder.

Conclusion

This review suggests a correlation between the glymphatic system and several psychiatric disorders: Schizophrenia, Depression, Anxiety Disorders, Sleep Disorders, Alcohol Use Disorder, Cocaine Use Disorder, Trauma-Related Disorders, and Autism Spectrum Disorders. Impairment of the glymphatic system could play a role in Trauma-Related Disorders, Alcohol Use Disorders, Cocaine Use Disorders, Sleep Disorders, Depression, and Autism Spectrum Disorders. It is important to implement research on this topic and adopt standardized markers and radio diagnostic tools.

Keywords

Glymphatic system
aquaporin-4
astrocytes
psychiatric disorders
mood disorders
depression
==== Body
pmc1 INTRODUCTION

In 2012, Iliff and et al. described for the first time the glymphatic system, a complex system located in the central nervous system (CNS) of mammals [1]. Due to the similarities with the peripheral lymphatic system, they coined the term glymphatic, referring to its two main components: the fluid and glial components, respectively represented by the subarachnoid cerebrospinal fluid (CSF), interstitial fluid (ISF) and astrocytes, and their interactions [2]. This unique network is composed of astroglial processes that create a layer surrounding all the arterioles, capillaries, and venules of the brain, forming perivascular tunnels [3-5]. The small perivascular spaces (PVSs) found between the processes and the vessel walls, through which ISF moves, provide CSF movement through the brain parenchyma, leading to osmotic clearance of metabolites [6, 7]. Specifically, regarding fluid movements, the CSF, produced mainly in the choroid plexus (CP), and the ISF, are drained into the so-called Virchow-Robin space (VRS), which is formed by the PVSs surrounding the superficial cerebral vessels and proximal penetrating vessels [8, 9]. From the VRS termination, CSF moves into the basal lamina surrounding the cerebral capillaries [10]. CSF and ISF end up draining from the CNS through a lymphatic pathway located in the dural meninges [11-15], as well as along nerve conduits in the cribriform plate, finally leading to the cervical lymphatic vessels [16] and ending into the superficial and deep cervical lymph nodes. The other main component of such systems is represented by astrocytes, which are essential components of the blood-brain barrier (BBB) that play a crucial role in the interaction between neurons and brain vessels [17]. Indeed, together with microglia, pericytes, endothelial cells and the basal lamina, astrocyte end-feet form the neurovascular unit (NVU) [4, 5]. In addition, astrocytic processes express aquaporin-4 (AQP-4), a channel that allows the exchange of water inside and outside the cell [18] and likely plays an important role in promoting the influx of perivascular CSF [19] into the brain parenchyma, where it mixes up with ISF [20]. Interestingly, the ultrastructure of astrocytic processes [21, 22] and AQP-4 channel expression appear to be regulated by a circadian rhythm [23]. Other essential functions of astrocytes are to remove brain waste compounds, to provide support and nutrients to neurons, being moreover involved in homeostatic processes, ions concentrations, repair mechanisms, synaptic regulatory systems [24-26] and regulation of cerebral blood flow around cerebral vessels [27, 28]. In summary, the glymphatic system allows CSF and ISF perfusion of the CNS and solute exchange between these two fluids, especially during sleep, and presumably under the influence of arterial pressure flow, vasomotion, and respiration [6, 7, 19, 29, 30]. Being the glymphatic system influenced by circadian regulation [31] and predominantly active during sleep, it has been hypothesized that an excess of catecholamines, especially prominent during wake time, may reduce the functioning of the glymphatic network [32, 33]. Astrocytes’ activity may also be regulated by the circadian rhythm, being adjacent to axons and neuron bodies during wakefulness, weaving smaller capillaries and leaving very little space between them [21, 22, 34]. In contrast, in deep physiological sleep, astrocytes contract, causing a significant increase in the space between compressed glial cells and neurons, allowing the CSF to flow intensely through brain tissue [21, 35, 36]. Therefore, the glymphatic system stands out as a critical tool for the elimination of macromolecule wastes, reactive oxygen species (ROS), cytokines, antigens, tau species, and amyloids [1, 2, 37] and the transport of solutes crucial for brain metabolism such as glucose [38], lipid signalling molecules [39], and apolipoprotein E [40]. Increasing evidence links dysfunction of the glymphatic system to CNS pathologies [41], as, for instance, malfunctioning of the glymphatic system has been highlighted in Parkinson's disease (PD) [42], Alzheimer's disease (AD) [43, 44] (Fig. 1), and in Multiple Sclerosis (MS) [45]. Moreover, the comorbidity of these disorders with psychiatric illness [46] and the common physiopathological trajectories, including increased oxidative stress [47, 48], neuroinflammation [49, 50], alterations in sleep [51, 52], circadian rhythms disruption [53, 54], and astrocyte damage [55, 56] leads to the hypothesis that such system may also be involved in the pathogenesis of psychiatric disorders alone. It is, therefore, noteworthy that several recent studies are discussing the potential correlation and involvement of the glymphatic system in the context of mood disorders [57, 58]. However, data on glymphatic system dysfunction and correlation with psychiatric disorders are still scarce and solid evidence is lacking. In this context, the present study aims to highlight current evidence on the correlation between the glymphatic system and psychiatric disorders, the dysfunction of this system in the context of psychiatric disorders, and to fill the gaps in the literature on this topic.

2 METHODS

A comprehensive review of the literature was carried out on Pubmed up to February 26, 2023. Considering the extensive aim of the study, we used Medical Subject Headings (MeSH) descriptors (“Glymphatic System” [Mesh] AND “Psychiatric Disorders” [Mesh]). To maximize the sensitivity of our study, we did not provide additional terms besides “Glymphatic System” and “Psychiatric Disorders.” Subsequently, the studies included were discussed with a narrative overview. Aiming to cover a broad literature overview and considering that strong evidence regarding the glymphatic system and psychiatric disorders is still lacking, a rapid comprehensive PRISMA-ScR scoping review, following the statement guidelines for scoping reviews [59], was identified as the best method to carry out the present study [60]. Articles selected were published between August 2012, when the glymphatic system was first described and defined [1], and February 2023. Only articles regarding the glymphatic system and psychiatric disorders, assessing the correlation between the glymphatic system and psychiatric disorders, or changes in psychiatric disorders and glymphatic system in a longitudinal perspective were included; finally, we included other studies that may provide useful information on clinically observable psychiatric manifestations related with the glymphatic system. Given the breadth of the topic and the aim of the study, in the present review, we only selected studies that addressed psychiatric disorders about the glymphatic system as a network and not about any single components of the glymphatic system (e.g., AQP-4, Astrocytes, CP, PVSs, VRS, CSF, ISF) or providing indirect measures of the glymphatic system functioning. In this review, we will include under the term “psychiatric disorder” all major psychiatric diseases (e.g., mood disorder (bipolar disorder, depression), Schizophrenia (SCZ) and psychosis, personality disorders (PDs), trauma and post-traumatic stress disorder (PTSD), anxiety, obsessive-compulsive disorder (OCD), autism spectrum disorders (ASDs), attention deficit and hyperactivity disorder (ADHD), substance abuse disorders (SUDs) (APA, 2013). Given the importance of sleep disorders (SDs) in the context of psychiatric disorders and the unique bidirectional relation between SDs and psychiatric disorders [51], articles providing useful information on SDs and sleep alterations as a manifestation of psychiatric disorders were also included. Considering the limited number of studies on this topic, we have included both clinical and preclinical studies. We excluded studies in languages other than English. Being the present study is a scoping review, the quality of the studies has not been addressed during the selection process [61]; therefore, meta-analysis, reviews, and systematic reviews were excluded. Purely narrative papers, editorials, book chapters, letters to editors, comments, and case reports, with small samples (< 10 subjects), were excluded as they would not provide better insight into the researched topic. Two independent reviewers screened citations for inclusion. Data extraction was conducted by one reviewer and verified by a second reviewer. Tables were then constructed, and articles were sorted out by authors, year, title, location of study, sample size, psychiatric disorder, the aim of the study, principal findings, and implications. The main findings of the included studies have been summarized in Table 1. Results were then discussed.

3 SEARCH RESULTS

The initial Pubmed search yielded a total of 212 results, while 3 additional titles were identified through other sources (website searching, citation tracking, and reference chaining). 3 records were excluded as not full text. During the screening process of the remaining 212 records, 154 were excluded as the article’s primary focus was not the correlation between the glymphatic system and psychiatric disorders, as their content was considered as irrelevant in the light of the present study's aim. Among the 58 remaining papers, 31 were excluded since they did not meet the above-listed inclusion criteria: 2 were systematic reviews, 23 were reviews, 2 were editorials, 1 was a study protocol, 1 was a viewpoint, and 2 were written in languages other than English, namely in Japanese and Russian. Of the final 27 eligible records, 7 were excluded as they did not provide adequate information about the relation between the glymphatic system and psychiatric disorders. 20 papers were finally identified as of particular interest. The selected articles are presented in Table 1 and discussed in the narrative overview. For specifics about the study design, consult Fig. (2).

4 NARRATIVE OVERVIEW

Among the 20 papers identified as suitable for this review, 9 were carried out in China, 5 in the United States (USA), 1 in China/USA, 1 in Italy, 1 in Norway, 1 in Australia, and 2 in Taiwan. 9 of the selected studies employed a murine sample, the others human samples. Regarding the psychiatric disorders taken into consideration, we found 2 articles focusing on SCZ, 1 on ASDs, 2 on depression, 1 on depression and trauma-related disorders, 1 on depression and anxiety, 2 on anxiety and SDs, 8 on SDs, 2 on Alcohol use disorder (AUD), and 1 on cocaine use disorder (CUD). Regarding the relationship between the glymphatic system and SCZ, Wu et al. conducted a case-control study in 2020 in Taiwan, recruiting 292 SCZ consecutive cases and 100 healthy controls (HC) of Southern Han Chinese descent [62]. For the association study, the 100 cases were matched for age, sex, and education to 100 of the HC. The aim was to investigate the relationship between AQP-4 gene polymorphisms and SCZ. In particular, three single nucleotide polymorphisms (SNPs) were found in SCZ patients belonging to the Southern Chinese Han population. When compared with HC, individuals with SCZ had a higher frequency of T alleles in rs1058424 and G alleles in rs3763043. In addition, an association between decreased risk of SCZ and AA genotype for both rs1058424 was found. The TCG haplotype was associated with a potential risk of developing SCZ, while the ACA haplotype was associated with a decreased risk and maintained statistical significance after Bonferroni correction. Therefore, this study was able to highlight an association between AQP-4 gene polymorphisms and SCZ in the Southern Han Chinese population. Wu et al. in 2018 carried out another study in Taiwan recruiting 190 patients diagnosed with SCZ of Southern Han Chinese descent [63]. The aim of the study was to investigate whether the gene polymorphisms and haplotype of AQP-4 influenced serum S100 calcium-binding protein B (S100B) level and clinical symptoms in patients with SCZ. Results showed that patients with the TAA haplotype of the AQP-4 polymorphism were likely to present increased serum S100B levels, as well as negative symptoms, and poor control of neuroinflammation. A logS100B level > 1.78 was moreover supposed to be sufficiently specific to predict a higher severity of negative symptoms. Therefore, results suggest that AQP-4 influences brain neuroinflammation in individuals with SCZ given its important role in maintaining BBB integrity, structure, and permeability. This study also provides a possible association between the involvement of genetic variations in the AQP-4 gene and the functional outcome of patients with SCZ. We found only one study addressing ASDs. This work, conducted in China in 2022 by Li et al., compared 30 children diagnosed with ASDs and 25 HC through diffusion tensor imaging (DTI) along the perivascular space (DTI-ALPS) [64]. The authors observed that patients with ASDs presented a significantly lower ALPS index than HC, suggesting that subjects had glymphatic dysfunction in patients with ASDs. This study underlines the importance of the DTI-ALPS approach in assessing the function of the glymphatic system in ASDs. Two studies included used a murine model to assess the role of the glymphatic system in the pathogenesis of depression. One was conducted in China in 2020 by Liu et al., using a sample of adult male mice, with the aim of testing the prediction that chronic unpredictable mild stress (CUMS) manifests with disturbed glymphatic function and whether dietary supplementation with polyunsaturated fatty acids (PUFAs) can ameliorate these deficits, alleviating the cognitive decline associated with depression [65]. The authors formulated also a secondary hypothesis: that dietary PUFA supplementation, but not escitalopram (ES), would restore glymphatic function and relieve depression-like behaviours and cognitive impairments in CUMS mice. Adult male C57BL/6 mice undergoing an eight-week CUMS paradigm were therefore treated either with PUFA or with ES. Results showed that significant depression-like behavioural symptoms and cognitive dysfunction in CUMS mice are accompanied by marked impairment of the glymphatic system. Even though the depression-like behavioural symptoms are relieved by treatment with the serotonin selective reuptake inhibitor (escitalopram), cognitive impairments in CUMS mice persist, unless the underlying disruption of the glymphatic system is restored. Daily oral supplementation with PUFA restores glymphatic system functions in CUMS mice and, therefore, relieves depression-like symptoms and cognitive deficits. Male mice were also studied by Xia et al. in 2017, in a work conducted in China, with the aim of identifying the pathogenetic relationship between depressive disorder and AD through a chronic unpredictable mild stress (CUMS) model, while assessing the function of the glymphatic pathway using fluorescence tracers [66]. The accumulation of endogenous mouse and exogenous human amyloid beta 42 (Aβ42) in CUMS-treated mice, with or without treatment with the antidepressant fluoxetine, was evaluated. Xia et al. observed that CUMS reduces AQP-4 expression in the cortex and hippocampus, and hypothesized that this may explain the altered glymphatic clearance, and the subsequent accumulation of Aβ42 in the brain, thus demonstrating that the dysfunction of the glymphatic system after injury by depressive disorder is a critical element in the development of AD, and the antidepressant fluoxetine may reverse this pathogenesis under chronic stress. The therapeutic effect of fluoxetine has also been associated with increased regulation of AQP-4 expression in astrocytes. However, while treatment with fluoxetine alone was effective in chronic stress, it had no effect in control mice. Ranti et al., in a work conducted in the USA in 2022, focused on the link between the glymphatic system’s neuroanatomy via PVS and trauma experience in patients with major depressive disorder (MDD), compared with HC, using 7-Tesla MRI and a semi-automated segmentation algorithm [67]. For this study, they recruited 21 patients with major depressive disorder (MDD) and 27 healthy controls (HC). Results yielded showed that the number of traumatic events correlated with the total PVS volume, both in patients with MDD and in the general population. Such results are suggestive not only of a relationship between glymphatic dysfunction, especially related to BBB integrity and psychological trauma but also that glymphatic impairment may play a role in trauma-related symptomatology. After sorting for age and sex, the number of traumatic events, specifically those eliciting fear, helplessness, or horror, was found to be positively correlated with total PVS volume both in the population with MDD and in the overall study population. These results suggest that PVS could potentially be a useful biomarker for estimating symptom severity and its long-term impact on neuroanatomical structures in the context of psychological trauma and MDD. Chen et al., in a 2021 cross-sectional study from China, recruited 431 patients with PD from Beijing Tiantan Hospital from May 2016 to August 2019, with the aim to explore the multi-dimensional effects of cerebral small vessel disease (CSVD) on PD outcomes, including depression and anxiety [68]. Patients with idiopathic PD underwent complete magnetic resonance imaging (MRI) examination necessary for evaluating CSVD and fulfilled, among others, Hamilton Anxiety Rating Scale (HAMA) and Hamilton Depression Rating Scale (HAMD) questionnaires. Significant associations were observed between the CSVD burden and HAMA score, as well as between the CSVD burden and HAMD score in multivariable model 2, while only a tendency toward a significant association was found in model 1. The study then concluded the total CSVD burden was significantly associated with depression/anxiety in patients with PD. Two studies deepened the relationship between the glymphatic system, SDs, and anxiety using a murine model. In particular, Liu et al., in a study conducted in China in 2017, tested the effect of continuous theta burst stimulation (cTBS) on a mouse sleep deprivation model [69]. The researchers studied the effect of cTBS on glymphatic pathway clearance in normal and in sleep- deprivation C57BL/6J mice, detecting AQP-4 polarization by immunofluorescence, and assessing anxiety-like behaviors trough open field (OF) tests. Sleep deprivation seems to reduce influx efficiency along the PVS, disturb AQP-4 polarization and induce anxiety-like behaviors. cTBS significantly attenuated the decrease in efficiency of solute clearance usually incurred with sleep deprivation, restored the loss of AQP-4 polarization and improved anxiety-like behavior in sleep-deprived animals. Results implied that cTBS had potential protective action against neuronal dysfunction, including anxiety-like behavior induced by SDs. Vasciaveo et al. in a work conducted in Italy in 2023, analyzed the effect of sleep fragmentation in wild-type and 5xFAD mouse models [70]. The OF tests were used to assess anxiety‐like behavior and spontaneous motor activity in all groups. Fisher’s multiple comparison tests revealed increased anxiety in fragmented (F) 5xFAD mice by reducing the time spent in the open arms, when compared to not fragmented (NF) 5xFAD and F-wt mice, which in contrast spent more time in the open arms compared to their control group (NF-wt). Sleep fragmentation induces a general acceleration of AD progression in 5xFAD mice, while in wild-type mice it affects cognitive behaviors in particular learning and memory. Results from this study, therefore, demonstrate how AQP-4 modulation is a crucial player of the glymphatic system activity, and sleep fragmentation differentially affects AQP-4 expression, and such influence varies according to the stage of the disease, where an up-regulation has been observed in younger animals, while such change could not be detected in older ones. Among the selected studies, 8 focused on the relation between glymphatic alterations and SDs. 2 of such studies employed a murine model, while 6 human samples. Achariyar et al. carried out a study in 2016 in the USA employing a mouse model in order to establish whether apoE in CSF, secreted by the CP, is homogeneously distributed into the brain and whether this distribution pattern was altered by sleep deprivation [40]. Results highlighted the contribution of glymphatic fluid as a transporting system involved in the delivery of CP/CSF-derived human apoE to neurons and how sleep deprivation suppresses glymphatic CSF-derived apoE distribution and clearance into the brain. To better delineate the role of AQP-4-mediated glymphatic clearance impairments in the brain following chronic sleep insufficiency, Zhang et al., in a work conducted in the USA and China in 2020, investigated glymphatic transport and accumulation of Aβ and Tau proteins following 7 days of sleep disruption [71]. They then proceeded to assess the pathophysiological consequences of AQP-4 deletion in this process using a sample of adult AQP-4-null mice and a control group of wild‐type (WT) mice. AQP-4 deletion resulted in an impairment of glymphatic transport and accumulation of β‐amyloid and Tau proteins in the brain following sleep disruption. AQP-4-null sleep-deprived mice, when compared with WT‐sleep-deprived mice, presented severe activation of microglia, neuroinflammation, synaptic protein loss in the hippocampus, as well as decreased working memory. AQP-4‐mediated glymphatic clearance ameliorates brain impairments caused by abnormal accumulation of metabolic wastes following chronic sleep deprivation. Thus, it could be considered a potential target for sleep‐related disorders. Siow et al. conducted a cross-sectional study recruiting 84 participants aged 60 or older in China in 2022 to explore the associations between human glymphatic function, sleep, neuropsychological performance, and cerebral gray matter volumes [72]. N2 phase sleep duration and the apnea-hypopnea index were independently associated with DTI-ALPS. Higher DTI-ALPS was associated with better Everyday Cognition (ECog) language scores and better Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) word list learning delayed recall subtest scores after covarying for age and education. Higher DTI-ALPS was also associated with higher gray matter volume after controlling for normal variations due to age, sex, and total intracranial volume. Significant associations were identified between glymphatic function and sleep, underlying the importance of sleep for brain health. This study also revealed associations between DTI-ALPS, neuropsychological performance, and cerebral gray matter volumes, suggesting the potential of DTI-ALPS as a biomarker for cognitive disorders. To study whether MRI-visible enlarged PVS could be useful neuroimaging markers to predict cognitive impairment in chronic insomnia patients, Wang et al. in China in 2022, compared 156 patients with chronic insomnia and 79 age-matched healthy individuals [73]. Reported results demonstrated MRI-visible enlarged PVS in the frontal cortex, centrum semiovale, basal ganglia, and hippocampus of chronic insomnia patients with impaired cognition (ICG when compared with normal cognition (NCG) patients. The increased MRI-visible enlarged PVS in the frontal cortex, centrum semiovale, and basal ganglia were also associated with the increased CSF Aβ42, t-tau, and p-tau levels in ICG patients. MRI-visible enlarged PVS in the basal ganglia, and centrum semiovale had high sensitivity and specificity in distinguishing ICG chronic insomnia patients from the NCG group. In conclusion, MRI-visible enlarged PVS in the basal ganglia and centrum semiovale might be valuable imaging markers to predict cognitive impairment in chronic insomnia patients. To explore the role of AQP-4 in AD, Rainey-Smith et al. investigated in a study conducted in 2018 in Australia, genetic variation across the AQP-4 gene with a particular focus on the relationship with, and between, sleep quality and quantity and brain Aβ burden [74]. This cross-sectional study recruited 462 participants aged 60 years or older, among which 222 also underwent Αβ imaging performed via positron emission tomography (PET) and genetic data were derived from a genome-wide SNPs array. Sleep quality was assessed with the Pittsburg Sleep Quality Inventory (PSQI). One AQP-4 variant, rs72878776, was associated with poorer overall sleep quality, while several SNPs moderated the effect of sleep latency (rs491148, rs9951307, rs7135406, rs3875089, rs151246) and duration (rs72878776, rs491148 and rs2339214) on brain Aβ-amyloid burden. This study demonstrated how genetic variation of AQP-4 is crucial in the relationship between self-reported sleep quality and brain Aβ burden as assessed by PET in cognitively normal older adults. The aim of the study conducted by Piantino et al. in 2021 in the USA was to explore the relationship between the number of mild traumatic brain injuries (mTBIs), poor sleep, and PVS burden in a cohort of Iraq/Afghanistan Army veterans after adjustment for clinically relevant covariates, as well as to establish the correlation between PVS burden and persistent postconcussive symptoms in this cohort [75]. To achieve such goals, the authors used a validated and automated image segmentation tool to quantify the number, volume, morphology, and location of PVS in the whole brain. An analysis of MRI data was then performed, and sleep quality was assessed by means of the PSQI. The number of mTBIs sustained in the military is associated with PVS burden, and this relationship is modulated by poor sleep. In the selected cohort, increased PVS burden is associated with worse post concussive symptoms, especially poor balance. Thus, quality of sleep modulates the relationship between the number of mTBIs sustained in the military and PVS volume. In persons with poor sleep, the increase in PVS volume observed with each subsequent mTBI is higher than in those who sleep well. Shokri-Kojori et al. in a work conducted in the USA in 2018, tested 20 healthy controls after a night of rested sleep, defined as rested wakefulness (RW) [76]. The aim of the study was to test whether one night of sleep deprivation would increase ABB in the hippocampus, which shows some of the earliest structural and functional changes in AD. The second objective of the study was to test the association between a history of poor sleep and higher ABB in the hippocampus, precuneus, and medial prefrontal cortex. One night of sleep deprivation, relative to baseline, resulted in a significant increase in Aβ burden in the right hippocampus and thalamus. These increases were associated with mood worsening following sleep deprivation, although they were not related to the genetic risk (APOE genotype) for AD. Eide et al. in a work conducted in Norway in 2020, compared a cohort of individuals undergoing one night’s total sleep deprivation with a cohort allowed unrestricted sleep and further followed both groups the following 24 h of unrestricted sleep to examine whether CSF tracer enhancement in human parasagittal dura is affected by sleep deprivation [77]. After one night of sleep deprivation (at 24 h), there was neither evidence for altered tracer enrichment in the parasagittal dura nor after a day of unrestricted sleep (at 48 h). The hypothesis of altered molecular egress to parasagittal dura after sleep deprivation was therefore not supported by this study. One of the selected studies, carried out by Chen et al. in China in 2020, focused on CUD [78]. Using a mouse model of noncontingent cocaine exposure, the research group evaluated alteration in glymphatic function, including CSF-ISF exchange and solute clearance from the brain, during repeated cocaine exposure and after withdrawal. This study found that the glymphatic system is consistent impairments caused by cocaine use, observable even after a seven-day withdrawal period. Such changes may be due to the deceleration and reduction of cerebral blood flow, decrease of the cerebral arterial wall pulsatility, astrogliosis, and the loss of AQP-4 polarity. These results suggest a multimodal mechanism through which cocaine impairs the glymphatic function, which may contribute to the development of neurocognitive disorders in patients with cocaine addiction. Our review included 2 papers studying the correlation between the glymphatic system and AUD, both conducted employing mice samples. Specifically, Lundgaard et al., in the USA in 2018, studied the effects of acute and chronic ethanol exposure and withdrawal from chronic ethanol exposure on glymphatic function [79]. In particular, they investigated glymphatic function in awake mice that had undergone acute and chronic ethanol exposure or chronic exposure followed by 24 hours of withdrawal. Low doses of chronic ethanol intake were associated with a significant decrease in GFAP expression, with little change in the cytokine profile, when compared with the saline group. These observations suggest that ethanol has a J-shaped effect on the glymphatic system, whereby low doses of ethanol increase glymphatic function. Conversely, chronic ethanol intake induced reactive gliosis and perturbed glymphatic function, which may contribute to and higher risk of developing dementia. Interestingly, this study found that the suppression of glymphatic function was not permanent and could be restored at 24 h after termination of chronic binge alcohol administration. The other study was conducted in China in 2020 by Liu et al., with the aim of investigating the exact mechanisms by which acute and chronic alcohol exposure impairs glymphatic function in the brain [80]. The glymphatic function seems to be impaired by acute and chronic alcohol application through different mechanisms. Acute alcohol intake reduces the influx and efflux function of the glymphatic system, possibly through stimulating the release of β-endorphin (β-EP) by and decreasing cerebrovascular pulsatility, while chronic alcohol consumption leads to activation of astrocytes and a widespread loss of perivascular AQP-4 polarization in the brain, resulting in an irreversible impairment of the glymphatic function. The reduction in the glymphatic function and CSF-ISF exchange may decrease the efficiency in the clearance of interstitial solutes, which could lead to solute accumulation such as Aβ deposition in the brain, thus contributing to the development of cognitive decline and dementia in chronic alcohol abusers. Conversely, this study found that the loss of perivascular AQP-4 polarization in the chronic binge-level alcohol-treated animals persisted even after 2 weeks of withdrawal.

5 DISCUSSION

This study aims to provide an overview of currently available studies investigating the relationship between the glymphatic system and psychiatric disorders. Regarding clinical studies, our review showed how the glymphatic system plays a role in SCZ, depression, anxiety disorders, SDs, AUD, trauma-related disorders, and ASD. Regarding preclinical studies, our work showed how the glymphatic system is involved in AUD, CUD, SDs, anxiety disorders and depression. Taken together, results observed in our review revealed how the glymphatic system plays a role in several psychiatric disorders, such as SCZ, depression, anxiety disorders, SDs, AUD, CUD, trauma-related disorders, and ASDs [33, 40, 62, 63, 65-79, 81]. Instead, in relation to other disorders (ADHD, OCD, bipolar disorder, PDs, and PTSD), no scientific evidence is currently available. Some of the considered studies suggested alteration of the glymphatic system in the context of some psychiatric disorders. Specifically, our findings suggest the involvement of glymphatic system impairment in trauma-related disorders, AUD, ASD, CUD, SDs, and depression [33, 65-67, 69, 70, 72, 78, 79, 81]. There are some considerations that must be made to discuss our results. Psychiatric disorders often present alterations in circadian rhythms [54], sleep alterations [51], increased oxidative stress [48], neuroinflammation [49], alterations in monoamines [82] and impaired glutamate secretion [83], and microglial and astrocytic damage [55, 84]. All the above-mentioned alterations could be correlated with, and possibly compromised by, dysfunctions of a single component of the glymphatic system but also related to impairments of the system itself [58, 85]. Hence, our study confirms the role of AQP-4 as a key component of the glymphatic system and its potential role as a marker of glymphatic impairment, also in the context of psychiatric disorders [62, 63, 70, 71, 74, 86, 87]. Furthermore, our study sheds light on the possible reliability of DTI-ALPS employment to assess glymphatic function [72, 81, 88]. Moreover, the role of TBI is a risk factor for psychiatric disorders in relation to glymphatic alterations [75, 89, 90]. Results from our review also confirm the close interrelationship between psychiatric and neurologic disorders, which could be quite likely mediated by the glymphatic system, confirming, for instance, the risk of dementia developing in the context of a psychiatric disorder [33, 46, 65, 66, 68, 72, 78, 79, 91]. The reported involvement of SDs [85] in the impairment of the glymphatic system confirms the role of this cross-system in the context of psychiatric illness, given the central role of SDs in the development of psychiatric diseases [51, 92-94], possibly through alterations in the glymphatic system itself, as it has already been hypothesized for mood disorders [95]. Specifically, when approaching depression under the glymphatic system perspective, data from our review seem consistent with the hypothesis that cognitive alterations found in depression could be considered as a prodrome of dementia itself [96]. Such thesis is supported by findings of markers of astroglial damage, such as S100 β and glial fibrillar acid protein (GFAP), along with alterations in AQP-4 expression [97, 98] and with alterations in choroid plexus (CP) morphology [99] found both in dementia and in depressed patients presenting cognitive alteration [100-102]. In addition, our study supports the role that restoration of the gut microbiome axis and supplementation of nutrients, such as PUFAs and Omega-3, may play in alleviating symptoms of depression [103] and modulating the glymphatic system [71]. Regarding anxiety disorders, similar considerations to those previously made for depression can be made, especially regarding the role of AQP-4 [104], astrocytes [105] and neuroinflammation [106]. Available studies on SCZ suggest that increased S100 β levels in CSF and serum may be found in subjects with early-onset SCZ [107], while astrocyte damage could play a role in the development of the disorder [108]. Regarding CUD and AUD, there is consistency in the literature regarding the involvement of AQP-4, along with astrogliosis and neuroinflammation, in addictive behavior [109-111]. Our data on ASDs seem compatible with other studies, including those revealing increased extra-axial CSF volume in children with normal-to-high risk of manifesting ASDs [112], as well as astrocyte involvement, as demonstrated by the presence of markers of astrocyte damage, and AQP-4 in the brains of ASDs subjects [113]. In addition, although no clarifying data on PTSD were found, findings on glymphatic system alteration in trauma-related disorders and glymphatic system-related sleep alterations in a population at risk for PTSD, such as veterans, suggest the need for further investigation. Supporting such hypothesis, some data report indirect measures of glymphatic system impairment in PTSD [81] and alterations in norepinephrine secretion during the arousal state [114]. Despite a clear correlation has not been demonstrated yet, data on anxious behavior after fragmented or deprived sleep, and manic-like behaviors that were induced in mice by sleep fragmentation, shed light on potential involvement in bipolar disorder [115, 116], which would be consistent with the expression of markers of astroglial damage [117] and AQP-4 altered gene expression in bipolar disorder individuals [98]. In light of a growing interest in this topic, we also found a preprint study on the correlation between ADHD and the glymphatic system [118] and an abstract on SCZ and the glymphatic system [119], that were not included in this review for methodological reasons. Nevertheless, it is extremely important to outline and consider the limitations of the present study: several of the included studies included data obtained from a mouse model, and few studies yet are available on human samples, moreover, not all studies employed the same methodology for assessment nor the same markers, finally, many of the included studies were conducted in a cross-sectional manner, and thus could not address a direct causal relationship between impairment of the glymphatic system and psychiatric disorders. The lack of longitudinal studies, especially on subjects with a formal psychiatric diagnosis, stands out as a major limitation in obtaining specific and clarifying data, as it is crucial to consider the difficulty in determining whether glymphatic system impairments should be considered as consequences of psychiatric disease, or the impairment of such system could be actively participating in the pathogenesis of psychiatric pathologies.

CONCLUSION

In conclusion, the present review aims to highlight the role of the glymphatic system in the context of psychiatric disorders, while underlining the need for implementation of research on this topic, as well as for markers definition and adaptation of specific radio diagnostic tools. Future studies are needed to replicate on human samples all psychiatry-related glymphatic research carried out on murine models. Moreover, it seems of utmost importance to take into consideration homogeneous samples of patients, with a formal psychiatric diagnosis, or specific patient subgroups, within a longitudinal assessment to yield better information and implement our knowledge on this topic.

ACKNOWLEDGEMENTS

Declared none.

AUTHORS’ CONTRIBUTIONS

Conceptualization and design were performed by T.B., P.G., A.D.C., F.P., and A.M. Data extraction was conducted by T.B. and verified by A.M. and R.T. and D.D.B screened citations for inclusion. T.B., P.G., F.P., A.M., A.D.C. and C.D.A. wrote the main manuscript text and R.T. and F.P. prepared figures 1 and 2 and table 1. T.B., C.T., D.D.B, L.O., P.G., A.R. and F.P. developed methodology, formal analysis, and data curation. All authors contributed equally to the article. All authors read and approved the final manuscript.

LIST OF ABBREVIATIONS

AD Alzheimer's Disease

ADHD Attention Deficit and Hyperactivity Disorder

AQP-4 Aquaporin-4

ASDs Autism Spectrum Disorders

AUD Alcohol Use Disorder

Aβ42 Amyloid Beta 42

BBB Blood-brain Barrier

CERAD-NB Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery

CNS Central Nervous System

CP Choroid Plexus

CP Choroid Plexus

CSF Cerebrospinal Fluid

CSVD Cerebral Small Vessel Disease

cTBS Continuous Theta Burst Stimulation

CUD Cocaine Use Disorder

CUMS Chronic Unpredictable Mild Stress

DTI Diffusion Tensor Imaging

DTI-ALPS Along The Perivascular Space

ES Escitalopram

GFAP Glial Fribrillar Acid Protein

HAMA Hamilton Anxiety Rating Scale

HAMD Hamilton Depression Rating Scale

HC Healthy Controls

ICG Impaired Cognition

ISF Interstitial Fluid

MDD Major Depressive Disorder

MeSH Medical Subject Headings

MRI Magnetic Resonance Imaging

MS Multiple Sclerosis

mTBIs Mild Traumatic Brain Injuries

NCG Normal Cognition

NVU Neurovascular Unit

OCD Obsessive-compulsive Disorder

OF Open Field

PD Parkinson's Disease

PDs Personality Disorders

PET Positron Emission Tomography

PRISMA-ScR Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews

PSQI Pittsburg Sleep Quality Inventory

PTSD Post-traumatic Stress Disorder

PUFAs Polyunsaturated Fatty Acids

PVSs Perivascular Spaces

ROS Reactive Oxygen Species

RW Rested-wakefulness

S100B S100 Calcium-binding Protein B

SCZ Schizophrenia

SDs Sleep Disorders

SNPs Single Nucleotide Polymorphisms

SUDs Substance Abuse Disorders

USA United States

VRS Virchow Robin Space

WT Wild‐type

β-EP β-endorphin

CONSENT FOR PUBLICATION

Not applicable.

STANDARDS OF REPORTING

PRISMA guidelines and methodology were followed.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

SUPPLEMENTARY MATERIAL

Supplementary material is available on the publisher’s website along with the published article.

Fig. (1) Common physiopathological trajectories between Psychiatric Disorders and Glymphatic System involvement. Adapted from Schubert et al. 2019.

Fig. (2) PRISMA 2020 flow diagram of included studies.

Table 1 Glymphatic system and psychiatric disorders characteristics of the studies included in the review.

Characteristics of Studies Assessing the Relation between the Glymphatic System and Psychiatric Disorders (n = 20)	
Authors, Year/
References	Title	Location of Study	Sample Size	Psychiatric Disorder	Aim of the Study	Principal Findings	Implications	
Achariyar et al., 2016 [40]	Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation	USA	Male C57BL/6 J and NG2-DsRed (Tg(Cspg4-Ds Red.T1)1Akik/J) mice.	Sleep
Disorders	To establish whether apoE in CSF, secreted by the choroid plexus, is distributed into the brain, and whether this distribution pattern was altered by sleep
deprivation.	The glymphatic fluid transporting system contributes to the delivery of choroid plexus/CSF-derived human apoE to neurons.	Sleep deprivation suppresses glymphatic CSF-derived apoE distribution into the brain and its clearance.	
Wu et al., 2020 [62]	Polymorphisms in the Human Aquaporin 4 Gene Are Associated with Schizophrenia in the Southern Chinese Han Population: A Case-Control Study	Taiwan	292 patients with Schizophrenia and 100 healthy controls.	Schizophrenia	To study the relationship of AQP4 gene polymorphisms and Schizophrenia (SCZ).	Three SNPs were found. In comparison to healthy controls, patients had higher T-allele frequencies at rs1058424 and
G-allele frequencies at rs3763043. Furthermore,
there is an association between the decreased risk of SCZ and the AA genotype at both rs1058424.
The TCG haplotype was associated with a potential risk of SCZ, while the ACA haplotype was associated with a decreased risk of SCZ and retained statistical significance after Bonferroni correction.	An etiological reference for schizophrenia is provided by the association between AQP4 gene polymorphisms and schizophrenia in the Southern Han Chinese population.	
Wu et al., 2018 [63]	Human Aquaporin 4 Gene Polymorphisms and Haplotypes Are Associated With Serum S100B Level
and Negative Symptoms of Schizophrenia in a Southern Chinese Han Population	Taiwan	190 patients with Schizophrenia	Schizophrenia	To investigate whether the gene polymorphisms and haplotype of AQP4 are associated with serum S100 calcium-binding protein B (S100B) level and clinical symptoms in patients with schizophrenia (SCZ).	Patients with the TAA haplotype of the AQP4 polymorphism are likely to have increased serum S100B level, negative symptoms and poor control of neuroinflammation. A logS100B level >1.78 may be sufficiently specific to predict a higher severity of negative symptoms.	AQP4 seems to influence brain neuroinflammation in SCZ because of its important role in maintaining BBB integrity, structure, and permeability. This study provides possible association between the involvement of genetic variations in
the AQP4 gene and
the functional outcome
of patients with schizophrenia.	
Li et al., 2022 [64]	Children with autism spectrum disorder present glymphatic system dysfunction evidenced by diffusion tensor imaging along the perivascular space	China	30 children with Autism Spectrum Disorder and 25 healthy controls in this study.	Autism Spectrum Disorder	To assess glymphatic system function in autism spectrum disorder (ASD) compared to healthy controls through diffusion tensor imaging (DTI) along the perivascular space (DTI-ALPS).	The DTI-ALPS index was strongly and positively associated with age. In patients with ASD, there is a glymphatic system dysfunction.
This is intimately correlated to age.	In patients with ASD, there is a glymphatic system dysfunction.
This is intimately correlated to age. This study suggests the importance of the DTI-ALPS approach in assessing the function of the glymphatic system in ASD.	
Liu et al., 2020 [65]	Polyunsaturated fatty acid supplement alleviates depression-incident cognitive dysfunction by protecting the cerebrovascular and glymphatic systems	China	Adult male C57BL/6 mice.	Depression	To test the prediction
that the chronic unpredictable mild stress (CUMS) manifests in disturbed glymphatic function and that
dietary supplementation with Polyunsaturated fatty acid (PUFA)
could improve these deficits while alleviating the depression-associated cognitive decline.	PUFA supplementation rescued depression-like behaviors of CUMS mice, reduced neuroinflammation and cerebrovascular dysfunction, ultimately improved cognitive performance, all of which accompanied by restoring glymphatic system function.	The CUMS depression model entails suppression of the glymphatic system. PUFA supplementation rescued most behavioral signs of depression and
the associated cognitive dysfunction by restoring the underlying glymphatic system disruption and protecting cerebral vascular function.	
Xia et al., 2017 [66]	Mechanism of depression as a risk factor in the development of Alzheimer's disease: the function of AQP4 and the glymphatic system	China	Male Mice C57BL/6 and FVB/NTg (GFAP-GFP) 14Mes/J.	Depression	To identify the pathogenetic relationship between depressive disorder and Alzheimer’s disease (AD) through a chronic unpredictable mild stress (CUMS) model to determine the function of the glymphatic pathway by using fluorescence tracers. Immunohistochemistry was used to assess the accumulation of endogenous mouse and exogenous human amyloid beta 42 (Aβ42) in CUMS-treated mice
with or without
treatment with
antidepressant
fluoxetine.	Glymphatic pathway circulation was impaired in mice treated with CUMS; moreover, glymphatic pathway dysfunction suppressed Aβ42 metabolism, because the accumulation of endogenous and exogenous Aβ42 was increased in the brains of the CUMS-treated mice. However, treatment with fluoxetine reversed these destructive effects of CUMS on the glymphatic system. In anhedonic mice, the expression of the water channel aquaporin 4 (AQP4), a factor in glymphatic pathway dysfunction, was down-regulated in cortex and hippocampus.	The dysfunction of the glymphatic system suggested why a history of depression may be a strong risk factor for AD in anhedonic mice.	
Ranti
et al., 2022 [67]	Perivascular spaces as a marker of psychological trauma in depression: A 7-Tesla MRI study	USA	21 patients with Major Depressive Disorder and 27 healthy controls.	Depression/ Trauma related-disorders	Investigated the link between glymphatic neuroanatomy via perivas-cular spaces (PVS) and trauma experience in patients with major depressive disorder (MDD) and
in healthy controls
using 7-Tesla MRI
and a semi-automated segmentation
algorithm.	The number of traumatic
events was correlated with
total PVS volume in MDD patients and the overall
population. The number of traumatic events eliciting horror was positively correlated with total PVS volume in MDD patients and the overall population. Age correlated positively with PVS count, PVS total volume, and PVS density in all participants.	Results suggest a relationship between glymphatic dysfunction related to blood brain barrier (BBB) integrity and psychological trauma, and that glymphatic impairment may play a role in trauma-related symptomatology.	
Chen
et al., 2021 [68]	Cerebral small vessel disease may worsen motor function, cognition, and mood in Parkinson's disease	China	421 patients with Parkinson
disease.	Depression/
Anxiety	To explore the multi-dimensional effects of Cerebral Small Vessel Disease (CSVD) on Parkinson’s Disease (PD) outcomes (motor, cognition, and depression/anxiety).	Comorbid CSVD may
contribute to multi-dimensional dysfunction in patients with PD and different CSVD imaging markers may play distinct roles in PD outcomes.
The management of cerebral vascular disease may be
crucial to maintain motor
and non-motor functions
in PD.	The total CSVD burden was significantly associated with depression/anxiety in patients with PD.	
Liu et al., 2017 [69]	Continuous theta burst stimulation facilitates the clearance efficiency of the glymphatic pathway in a mouse model of sleep deprivation	China	108 males C57BL/6 mice.	Sleep disorders/
Anxiety	To explore the effect
of continuous theta
burst stimulation
(cTBS) with a two-photon in vivo
imaging on glymphatic pathway clearance in normal and SD C57BL/6J mice.
Aquaporin-4 (AQP4) polarization was detected by immunofluorescence.
Anxiety-like behaviors were measured using open field tests.	SD reduced influx efficiency along the peri-vascular space (PVS), disturbed AQP4
polarization and induced anxiety-like behaviors. Continuous theta burst stimulation (cTBS) significantly attenuated the decrease in efficiency of solute clearance usually incurred with SD, restored the loss of AQP4 polarization and improved anxiety-like behavior in SD animals.	Results implied that cTBS had the potential to protect against neuronal dysfunction, including anxiety-like-behavior, induced by sleep disorders.	
Vasciaveo et al., 2023 [70]	Sleep fragmentation affects glymphatic system through the different expression of AQP4 in wild type and 5xFAD mouse models	Italy	Two-months-old no carrier male mice (control mice) and 2- and 6-month-old male B6SJL-Tg (APPSwFlLon, PSEN1 ∗ M146L ∗ L286V) 6799Vas/Mmjax (5xFAD) mice.	Sleep Disorders/
Anxiety	To analyze the effect of sleep fragmentation in wild type and 5xFAD mouse models. Anxiety-like behaviors were measured using open field tests.	Fisher's multiple comparison test revealed increased anxiety in fragmented (F) 5xFAD mice by reducing the time spent in the open arms compared to not fragmented (NF) 5xFAD and
F-wt mice, which in contrast spent more time in the open arms compared to their control group (NF-wt). Sleep fragmentation induces a general acceleration of AD progression in 5xFAD mice, while in wild type mice it affects cognitive behaviors in particular learning and memory.	Aquaporin-4 (AQP4) modulation is a crucial player of the glymphatic system activity. In particular, sleep fragmentation differentially affects aquaporin-4 channel (AQP4) expression
according to the stage
of the disease, with an
up-regulation in
younger animals, while such change cannot be detected in older ones. After sleep fragmentation, 5xFAD mice manifested an increase in anxious
and hyperactive
behavior.	
Zhang
et al., 2020 [71]	Aquaporin 4 deletion exacerbates brain impairments in a mouse model of chronic sleep disruption	China/ USA	Adult AQP4 null mice and wild-type (WT) mice.	Sleep Disorders	To investigate pathophysiological roles of astroglial aquaporin 4 (AQP4), a functional regulator of glymphatic clearance, in a mouse model of chronic sleep disruption (SD).	Aquaporin 4 deletion resulted
in an impairment of glymphatic transport and accumulation of
β‐amyloid and Tau proteins in the brain following SD. AQP4 null SD mice exhibited severe activation of microglia,
neuroinflammation, and
synaptic protein loss in the hippocampus, as well as
decreased working memory, compared with WT-SD
mice.	AQP4-zmediated glymphatic clearance ameliorates brain impairments caused by abnormal accumulation of metabolic wastes following chronic SD, thus serving as a potential target for sleep‐related disorders.	
Siow
et al., 2022 [72]	Association of Sleep, Neuropsychological Performance, and Gray Matter Volume with Glymphatic Function in Community-Dwelling Older Adults	China	84 participants aged 60 years or older.	Sleep Disorders	To explore the associations between human glymphatic function, sleep, neuropsychological performance, and cerebral gray matter volumes.	N2 sleep duration and the apnea-hypopnea index were independently associated with DTI-ALPS. Higher DTI-ALPS was associated with better ECog language scores and better CERAD-NB word list learning delayed recall subtest scores after covarying for age and education. Higher DTI-ALPS was also associated with higher gray matter volume after controlling for age, sex, and total intracranial volume.	Significant associations were identified between glymphatic function and sleep, stressing the importance of sleep for brain health. This study also revealed associations between DTI-ALPS, neuropsychological performance, and cerebral gray matter volumes, suggesting the potential
of DTI-ALPS as a
biomarker for cognitive disorders.	
Wang
et al., 2022 [73]	MRI-visible enlarged perivascular spaces: imaging marker to predict cognitive impairment in older chronic insomnia patients	China	156 patients with chronic insomnia and 79 age-matched healthy individuals.	Sleep
Disorders	To explore whether MRI-visible enlarged perivascular spaces (EPVS) could be imaging markers to predict cognitive impairment in chronic insomnia patients.	MRI-visible EPVS in the frontal cortex, centrum semiovale, basal ganglia, and hippocampus of chronic insomnia patients with impaired cognition (ICG) significantly increased than that in normal cognition (NCG) patients. The increased MRI-visible EPVS in the frontal cortex, centrum semiovale, and basal ganglia were also associated with the increased CSF Aβ42, t-tau, and p-tau level in ICG patients. MRI-visible EPVS in the basal ganglia and centrum semiovale had high sensitivity and specificity in distinguishing ICG chronic insomnia patients from those with NCG.	MRI-visible EPVS in the basal ganglia and centrum semiovale might be valuable imaging markers to predict cognitive impairment in chronic insomnia patients.	
Rainey-Smith
et al., 2018 [74]	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden	Australia	462 aged 60 years or older.	Sleep
Disorders	To determine whether genetic variation
within AQP4 moderated the relationship
between PSQI-derived self-reported sleep quality and brain
Aβ burden as assessed by PET in cognitively normal older adults
of the AIBL
study.	One AQP4 variant, rs72878776, was associated with poorer overall sleep quality, while several SNPs moderated
the effect of sleep latency (rs491148, rs9951307, rs7135406, rs3875089, rs151246) and duration (rs72878776, rs491148 and rs2339214) on brain
Aβ-amyloid burden.	This study suggests that genetic variation of AQP4 moderates the relationship between sleep parameters and brain Aβ burden.	
Piantino
et al., 2021 [75]	Link between Mild Traumatic Brain Injury, Poor Sleep, and Magnetic Resonance Imaging: Visible Perivascular Spaces in Veterans	USA	56 Iraq/
Afghanistan Veterans.	Sleep
Disorders	To determine the
relationship between
the number of mild traumatic brain injury (mTBI), poor sleep,
and PVS burden in a cohort of Iraq/
Afghanistan military veterans after adjusting for clinically relevant covariates and to
establish the
relationship between PVS burden and
persistent post-concussive symptoms
in this cohort.	The number of mTBIs sustained in the military is associated with PVS burden, and this relationship is modulated by poor sleep. In this cohort, increased PVS burden is associated with worse post concussive symptoms, particularly poor balance.	Quality of sleep modulates the relationship between the number of mTBIs sustained in the military and PVS volume. In persons with poor sleep, the increase in PVS volume observed with each subsequent mTBI is higher than in those who sleep well.	
Shokri-Kojori,
et al. 2018 [76]	β-Amyloid accumulation in the human brain after one night of sleep deprivation	USA	20 healthy controls tested after a night of rested sleep, referred to as rested-wakefulness (RW).	Sleep
Disorders	To assess the effect of one-night SD on brain ABB with PET-FBB in healthy controls and to compare the measures to baseline brain ABB captured at the same time of the day but following a night of rested sleep [referred to as rested-wakefulness (RW)]. To replicate the previously reported association between sleep history and brain ABB (when measured after RW).	One night of sleep deprivation, relative to baseline, resulted in a significant increase in Aβ burden in the right hippocampus and thalamus. These increases were associated with mood worsening following sleep deprivation, but were not related to the genetic risk (APOE genotype) for
Alzheimer’s disease. Baseline brain Aβ burden (ABB) in a range of subcortical regions and the precuneus was inversely associated with reported night sleep hours.	There is an association between SD-related increases in ABB and mood worsening supporting the functional significance of elevated ABB.	
Eide et al., 2021 [77]	Cerebrospinal fluid egress to human parasagittal dura and the impact of sleep deprivation	Norway	One group of individuals (n = 7) underwent one night’s total sleep deprivation while a control group (n = 9) was allowed unrestricted sleep.	Sleep
Disorders	To examine whether CSF tracer enhancement in human parasagittal dura is affected by sleep deprivation.	After one night of sleep deprivation (at 24 h), there were neither evidence for altered tracer enrichment in the parasagittal dura, nor after a day of unrestricted sleep (at 48 h).	The hypothesis of altered molecular egress to parasagittal dura after sleep deprivation was not supported by this study.	
Chen et al., 2020 [78]	Cocaine-induced structural and functional impairments of the glymphatic pathway in mice	China	Adult male C57BL/6J mice.	Cocaine use disorder	To evaluate glymphatic function, including
CSF-ISF exchange and solute clearance from
the brain, using a mouse model of noncontingent cocaine exposure, during repeated cocaine exposure and after
withdrawal.	Cocaine exposure, substantially impaired glymphatic function including CSF-ISF exchange and solute clearance from the brain.	Cocaine exposure impairs clearance of waste from the brain, which may contribute to the development of neurocognitive disorders in patients with drug addictions.	
Lundgaard et al., 2018 [79]	Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake on glymphatic function	USA	Awake, behaving C57Bl6 mice.	Alcohol use disorder	To investigate the effects of acute and chronic ethanol exposure and withdrawal from chronic ethanol exposure on glymphatic function.	Acute and chronic exposure to 1.5 g/kg (binge level) ethanol dramatically suppressed glymphatic function in awake mice. Chronic exposure to 1.5 g/kg ethanol increased GFAP expression and induced mislocation of the astrocyte-specific water channel aquaporin 4 (AQP4), but decreased the levels of several cytokines. Glymphatic function increased in mice treated with 0.5 g/kg (low dose) ethanol following acute exposure, as well as after one month of chronic exposure.
Low doses of chronic ethanol intake were associated with a significant decrease in GFAP expression, with little change in the cytokine profile compared with the saline group.	Ethanol has a J-shaped effect on the glymphatic system whereby low doses of ethanol increase glymphatic function. Conversely, chronic 1.5 g/kg ethanol intake induced reactive gliosis and perturbed glymphatic function, which possibly may contribute to the higher risk of dementia observed in heavy drinkers.	
Liu et al., 2020 [80]	Experimental alcoholism primes structural and functional impairment of the glymphatic pathway	China	Adult male C57BL/6J mice (8أ12 weeks of age) and Aqp4-knockout mice on a C57BL/6.	Alcohol use disorder	To investigate the exact mechanisms by which acute and chronic binge alcohol exposure impairs the glymphatic function in the brain.	The elevated release of β-endorphin and reduced cerebrovascular pulsatility after acute alcohol administration may account for the impairment of the glymphatic function.
Chronic moderate alcohol consumption led to pronounced activation of astrocytes and a widespread loss of perivascular AQP4 polarization in the brain, which results in an irreversible impairment of the glymphatic function.	The study suggests that impaired glymphatic functions and reduced parenchymal Aβ clearance found in both acute and chronic alcohol treatment may contribute to the development of cognitive decline and dementia in alcoholism.
==== Refs
REFERENCES

1 Iliff J.J. Wang M. Liao Y. Plogg B.A. Peng W. Gundersen G.A. Benveniste H. Vates G.E. Deane R. Goldman S.A. Nagelhus E.A. Nedergaard M. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 2012 4 147 147ra111 10.1126/scitranslmed.3003748 22896675
2 Jessen N.A. Munk A.S.F. Lundgaard I. Nedergaard M. The glymphatic system: A beginner’s guide. Neurochem. Res. 2015 40 12 2583 2599 10.1007/s11064-015-1581-6 25947369
3 Mathiisen T.M. Lehre K.P. Danbolt N.C. Ottersen O.P. The perivascular astroglial sheath provides a complete covering of the brain microvessels: An electron microscopic 3D reconstruction. Glia 2010 58 9 1094 1103 10.1002/glia.20990 20468051
4 Troili F. Cipollini V. Moci M. Morena E. Palotai M. Rinaldi V. Romano C. Ristori G. Giubilei F. Salvetti M. Orzi F. Guttmann C.R.G. Cavallari M. Perivascular Unit: This must be the place. the anatomical crossroad between the immune, vascular and nervous system. Front. Neuroanat. 2020 14 17 10.3389/fnana.2020.00017 32372921
5 Iadecola C. Nedergaard M. Glial regulation of the cerebral microvasculature. Nat. Neurosci. 2007 10 11 1369 1376 10.1038/nn2003 17965657
6 Bohr T. Hjorth P.G. Holst S.C. Hrabětová S. Kiviniemi V. Lilius T. Lundgaard I. Mardal K.A. Martens E.A. Mori Y. Nägerl U.V. Nicholson C. Tannenbaum A. Thomas J.H. Tithof J. Benveniste H. Iliff J.J. Kelley D.H. Nedergaard M. The glymphatic system: Current understanding and modeling. iSci. 2022 25 9 104987 10.1016/j.isci.2022.104987 36093063
7 Iliff J.J. Wang M. Zeppenfeld D.M. Venkataraman A. Plog B.A. Liao Y. Deane R. Nedergaard M. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J. Neurosci. 2013 33 46 18190 18199 10.1523/JNEUROSCI.1592-13.2013 24227727
8 Mestre H. Kostrikov S. Mehta R.I. Nedergaard M. Perivascular spaces, glymphatic dysfunction, and small vessel disease. Clin. Sci. 2017 131 17 2257 2274 10.1042/CS20160381 28798076
9 Cherian I. Beltran M. Kasper E. Bhattarai B. Munokami S. Grasso G. Exploring the Virchow-Robin spaces function: A unified theory of brain diseases. Surg. Neurol. Int. 2016 7 27)(26 711 10.4103/2152-7806.192486 27857861
10 Barisano G. Lynch K.M. Sibilia F. Lan H. Shih N.C. Sepehrband F. Choupan J. Imaging perivascular space structure and function using brain MRI. Neuroimage 2022 257 119329 10.1016/j.neuroimage.2022.119329 35609770
11 Aspelund A. Antila S. Proulx S.T. Karlsen T.V. Karaman S. Detmar M. Wiig H. Alitalo K. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 2015 212 7 991 999 10.1084/jem.20142290 26077718
12 Iliff J.J. Goldman S.A. Nedergaard M. Implications of the discovery of brain lymphatic pathways. Lancet Neurol. 2015 14 10 977 979 10.1016/S1474-4422(15)00221-5 26376966
13 Louveau A. Smirnov I. Keyes T.J. Eccles J.D. Rouhani S.J. Peske J.D. Derecki N.C. Castle D. Mandell J.W. Lee K.S. Harris T.H. Kipnis J. Structural and functional features of central nervous system lymphatic vessels. Nature 2015 523 7560 337 341 10.1038/nature14432 26030524
14 Louveau A. Herz J. Alme M.N. Salvador A.F. Dong M.Q. Viar K.E. Herod S.G. Knopp J. Setliff J.C. Lupi A.L. Da Mesquita S. Frost E.L. Gaultier A. Harris T.H. Cao R. Hu S. Lukens J.R. Smirnov I. Overall C.C. Oliver G. Kipnis J. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 2018 21 10 1380 1391 10.1038/s41593-018-0227-9 30224810
15 Yankova G. Bogomyakova O. Tulupov A. The glymphatic system and meningeal lymphatics of the brain: new understanding of brain clearance. Rev. Neurosci. 2021 32 7 693 705 10.1515/revneuro-2020-0106 33618444
16 Kida S. Pantazis A. Weller R.O. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol. Appl. Neurobiol. 1993 19 6 480 488 10.1111/j.1365-2990.1993.tb00476.x 7510047
17 Cabezas R. Avila M. Gonzalez J. El-Bachá R.S. Báez E. García-Segura L.M. Jurado Coronel J.C. Capani F. Cardona-Gomez G.P. Barreto G.E. Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Front. Cell. Neurosci. 2014 8 211 10.3389/fncel.2014.00211 25136294
18 Ikeshima-Kataoka H. Neuroimmunological implications of AQP4 in astrocytes. Int. J. Mol. Sci. 2016 17 8 1306 10.3390/ijms17081306 27517922
19 Mestre H. Tithof J. Du T. Song W. Peng W. Sweeney A.M. Olveda G. Thomas J.H. Nedergaard M. Kelley D.H. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat. Commun. 2018 9 1 4878 10.1038/s41467-018-07318-3 30451853
20 Kress B.T. Iliff J.J. Xia M. Wang M. Wei H.S. Zeppenfeld D. Xie L. Kang H. Xu Q. Liew J.A. Plog B.A. Ding F. Deane R. Nedergaard M. Impairment of paravascular clearance pathways in the aging brain. Ann. Neurol. 2014 76 6 845 861 10.1002/ana.24271 25204284
21 Bellesi M. de Vivo L. Tononi G. Cirelli C. Effects of sleep and wake on astrocytes: clues from molecular and ultrastructural studies. BMC Biol. 2015 13 1 66 10.1186/s12915-015-0176-7 26303010
22 Tso M.C.F. Herzog E.D. Was Cajal right about sleep? BMC Biol. 2015 13 1 67 10.1186/s12915-015-0178-5 26303078
23 Pizarro A. Hayer K. Lahens N.F. Hogenesch J.B. CircaDB: A database of mammalian circadian gene expression profiles. Nucleic Acids Res. 2012 41 D1 D1009 D1013 10.1093/nar/gks1161 23180795
24 Kruyer A. Kalivas P.W. Scofield M.D. Astrocyte regulation of synaptic signaling in psychiatric disorders. Neuropsychopharmacology 2023 48 1 21 36 10.1038/s41386-022-01338-w 35577914
25 Verkhratsky A. Nedergaard M. Physiology of astroglia. Physiol. Rev. 2018 98 1 239 389 10.1152/physrev.00042.2016 29351512
26 Chiareli R.A. Carvalho G.A. Marques B.L. Mota L.S. Oliveira-Lima O.C. Gomes R.M. Birbrair A. Gomez R.S. Simão F. Klempin F. Leist M. Pinto M.C.X. The role of astrocytes in the neurorepair process. Front. Cell Dev. Biol. 2021 9 665795 10.3389/fcell.2021.665795 34113618
27 Koehler R.C. Roman R.J. Harder D.R. Astrocytes and the regulation of cerebral blood flow. Trends Neurosci. 2009 32 3 160 169 10.1016/j.tins.2008.11.005 19162338
28 Masamoto K. Unekawa M. Watanabe T. Toriumi H. Takuwa H. Kawaguchi H. Kanno I. Matsui K. Tanaka K.F. Tomita Y. Suzuki N. Unveiling astrocytic control of cerebral blood flow with optogenetics. Sci. Rep. 2015 5 1 11455 10.1038/srep11455 26076820
29 Fultz N.E. Bonmassar G. Setsompop K. Stickgold R.A. Rosen B.R. Polimeni J.R. Lewis L.D. Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science 2019 366 6465 628 631 10.1126/science.aax5440 31672896
30 van Veluw S.J. Hou S.S. Calvo-Rodriguez M. Arbel-Ornath M. Snyder A.C. Frosch M.P. Greenberg S.M. Bacskai B.J. Vasomotion as a driving force for paravascular clearance in the awake mouse brain. Neuron 2020 105 3 549 561.e5 10.1016/j.neuron.2019.10.033 31810839
31 Hablitz L.M. Plá V. Giannetto M. Vinitsky H.S. Stæger F.F. Metcalfe T. Nguyen R. Benrais A. Nedergaard M. Circadian control of brain glymphatic and lymphatic fluid flow. Nat. Commun. 2020 11 1 4411 10.1038/s41467-020-18115-2 32879313
32 Hablitz L.M. Nedergaard M. The glymphatic system: A novel component of fundamental neurobiology. J. Neurosci. 2021 41 37 7698 7711 10.1523/JNEUROSCI.0619-21.2021 34526407
33 Liu G. Mestre H. Sweeney A.M. Sun Q. Weikop P. Du T. Nedergaard M. Direct measurement of cerebrospinal fluid production in mice. Cell Rep. 2020 33 12 108524 10.1016/j.celrep.2020.108524 33357428
34 O’Donnell J. Zeppenfeld D. McConnell E. Pena S. Nedergaard M. Norepinephrine: A neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem. Res. 2012 37 11 2496 2512 10.1007/s11064-012-0818-x 22717696
35 Nilsson C. Lindvall-Axelsson M. Owman C. Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res. Brain Res. Rev. 1992 17 2 109 138 10.1016/0165-0173(92)90011-A 1393190
36 Xie L. Kang H. Xu Q. Chen M.J. Liao Y. Thiyagarajan M. O’Donnell J. Christensen D.J. Nicholson C. Iliff J.J. Takano T. Deane R. Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science 2013 342 6156 373 377 10.1126/science.1241224 24136970
37 Mogensen F.L.H. Delle C. Nedergaard M. The glymphatic system (En)during inflammation. Int. J. Mol. Sci. 2021 22 14 7491 10.3390/ijms22147491 34299111
38 Lundgaard I. Li B. Xie L. Kang H. Sanggaard S. Haswell J.D.R. Sun W. Goldman S. Blekot S. Nielsen M. Takano T. Deane R. Nedergaard M. Direct neuronal glucose uptake heralds activity-dependent increases in cerebral metabolism. Nat. Commun. 2015 6 1 6807 10.1038/ncomms7807 25904018
39 Thrane V.R. Thrane A.S. Plog B.A. Thiyagarajan M. Iliff J.J. Deane R. Nagelhus E.A. Nedergaard M. Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain. Sci. Rep. 2013 3 1 2582 10.1038/srep02582 24002448
40 Achariyar T.M. Li B. Peng W. Verghese P.B. Shi Y. McConnell E. Benraiss A. Kasper T. Song W. Takano T. Holtzman D.M. Nedergaard M. Deane R. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Mol. Neurodegener. 2016 11 1 74 10.1186/s13024-016-0138-8 27931262
41 Natale G. Limanaqi F. Busceti C.L. Mastroiacovo F. Nicoletti F. Puglisi-Allegra S. Fornai F. Glymphatic system as a gateway to connect neurodegeneration from periphery to CNS. Front. Neurosci. 2021 15 639140 10.3389/fnins.2021.639140 33633540
42 Buccellato F.R. D’Anca M. Serpente M. Arighi A. Galimberti D. The role of glymphatic system in alzheimer’s and parkinson’s disease pathogenesis. Biomedicines 2022 10 9 2261 10.3390/biomedicines10092261 36140362
43 Reeves B.C. Karimy J.K. Kundishora A.J. Mestre H. Cerci H.M. Matouk C. Alper S.L. Lundgaard I. Nedergaard M. Kahle K.T. Glymphatic system impairment in alzheimer’s disease and idiopathic normal pressure hydrocephalus. Trends Mol. Med. 2020 26 3 285 295 10.1016/j.molmed.2019.11.008 31959516
44 Schubert J.J. Veronese M. Marchitelli L. Bodini B. Tonietto M. Stankoff B. Brooks D.J. Bertoldo A. Edison P. Turkheimer F.E. Dynamic 11C-PiB PET shows cerebrospinal fluid flow alterations in alzheimer disease and multiple sclerosis. J. Nucl. Med. 2019 60 10 1452 1460 10.2967/jnumed.118.223834 30850505
45 Carotenuto A. Cacciaguerra L. Pagani E. Preziosa P. Filippi M. Rocca M.A. Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability. Brain 2022 145 8 2785 2795 10.1093/brain/awab454 34919648
46 Hesdorffer D.C. Comorbidity between neurological illness and psychiatric disorders. CNS Spectr. 2016 21 3 230 238 10.1017/S1092852915000929 26898322
47 Uttara B. Singh A. Zamboni P. Mahajan R. Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 2009 7 1 65 74 10.2174/157015909787602823 19721819
48 Zhang X.Y. Yao J.K. Oxidative stress and therapeutic implications in psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013 46 197 199 10.1016/j.pnpbp.2013.03.003 23523744
49 Najjar S. Pearlman D.M. Alper K. Najjar A. Devinsky O. Neuroinflammation and psychiatric illness. J. Neuroinflammation 2013 10 1 816 10.1186/1742-2094-10-43 23547920
50 Mishra A. Bandopadhyay R. Singh P.K. Mishra P.S. Sharma N. Khurana N. Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside. Metab. Brain Dis. 2021 36 7 1591 1626 10.1007/s11011-021-00806-4 34387831
51 Krystal A.D. Psychiatric disorders and sleep. Neurol. Clin. 2012 30 4 1389 1413 10.1016/j.ncl.2012.08.018 23099143
52 Steele T.A. St Louis E.K. Videnovic A. Auger R.R. Circadian rhythm sleep–wake disorders: A contemporary review of neurobiology, treatment, and dysregulation in neurodegenerative disease. Neurotherapeutics 2021 18 1 53 74 10.1007/s13311-021-01031-8 33844152
53 Leng Y. Musiek E.S. Hu K. Cappuccio F.P. Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol. 2019 18 3 307 318 10.1016/S1474-4422(18)30461-7 30784558
54 Jones S.G. Benca R.M. Circadian disruption in psychiatric disorders. Sleep Med. Clin. 2015 10 4 481 493 10.1016/j.jsmc.2015.07.004 26568124
55 Zhang X. Alnafisah R.S. Hamoud A.R.A. Shukla R. McCullumsmith R.E. O’Donovan S.M. Astrocytes in neuropsychiatric disorders: A review of postmortem evidence. Adv. Neurobiol. 2021 26 153 172 10.1007/978-3-030-77375-5_8 34888835
56 McConnell H.L. Li Z. Woltjer R.L. Mishra A. Astrocyte dysfunction and neurovascular impairment in neurological disorders: Correlation or causation? Neurochem. Int. 2019 128 70 84 10.1016/j.neuint.2019.04.005 30986503
57 Zhang D. Li X. Li B. Glymphatic system dysfunction in central nervous system diseases and mood disorders. Front. Aging Neurosci. 2022 14 873697 10.3389/fnagi.2022.873697 35547631
58 Gu S. Li Y. Jiang Y. Huang J.H. Wang F. Glymphatic dysfunction induced oxidative stress and neuro-inflammation in major depression disorders. Antioxidants 2022 11 11 2296 10.3390/antiox11112296 36421482
59 Tricco A.C. Lillie E. Zarin W. O’Brien K.K. Colquhoun H. Levac D. Moher D. Peters M.D.J. Horsley T. Weeks L. Hempel S. Akl E.A. Chang C. McGowan J. Stewart L. Hartling L. Aldcroft A. Wilson M.G. Garritty C. Lewin S. Godfrey C.M. Macdonald M.T. Langlois E.V. Soares-Weiser K. Moriarty J. Clifford T. Tunçalp Ö. Straus S.E. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann. Intern. Med. 2018 169 7 467 473 10.7326/M18-0850 30178033
60 Munn Z. Peters M.D.J. Stern C. Tufanaru C. McArthur A. Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med. Res. Methodol. 2018 18 1 143 10.1186/s12874-018-0611-x 30453902
61 Arksey H. O’Malley L. Scoping studies: Towards a methodological framework. Int. J. Soc. Res. Methodol. 2005 8 1 19 32 10.1080/1364557032000119616
62 Wu Y.F. Sytwu H.K. Lung F.W. Polymorphisms in the human aquaporin 4 gene are associated with schizophrenia in the southern chinese han population: A case–control study. Front. Psychiatry 2020 11 596 10.3389/fpsyt.2020.00596 32676041
63 Wu Y.F. Sytwu H.K. Lung F.W. Human aquaporin 4 gene polymorphisms and haplotypes are associated with Serum S100B level and negative symptoms of schizophrenia in a southern chinese han population. Front. Psychiatry 2018 9 657 10.3389/fpsyt.2018.00657 30618856
64 Li X. Ruan C. Zibrila A.I. Musa M. Wu Y. Zhang Z. Liu H. Salimeen M. Children with autism spectrum disorder present glymphatic system dysfunction evidenced by diffusion tensor imaging along the perivascular space. Medicine 2022 101 48 e32061 10.1097/MD.0000000000032061 36482590
65 Liu X. Hao J. Yao E. Cao J. Zheng X. Yao D. Zhang C. Li J. Pan D. Luo X. Wang M. Wang W. Polyunsaturated fatty acid supplement alleviates depression-incident cognitive dysfunction by protecting the cerebrovascular and glymphatic systems. Brain Behav. Immun. 2020 89 357 370 10.1016/j.bbi.2020.07.022 32717402
66 Xia M. Yang L. Sun G. Qi S. Li B. Mechanism of depression as a risk factor in the development of Alzheimer’s disease: the function of AQP4 and the glymphatic system. Psychopharmacology 2017 234 3 365 379 10.1007/s00213-016-4473-9 27837334
67 Ranti D.L. Warburton A.J. Rutland J.W. Dullea J.T. Markowitz M. Smith D.A. Kligler S.Z.K. Rutter S. Langan M. Arrighi-Allisan A. George I. Verma G. Murrough J.W. Delman B.N. Balchandani P. Morris L.S. Perivascular spaces as a marker of psychological trauma in depression: A 7‐Tesla MRI study. Brain Behav. 2022 12 7 32598 10.1002/brb3.2598 35672958
68 Chen H. Wan H. Zhang M. Liu G. Wang X. Wang Z. Ma H. Pan Y. Feng T. Wang Y. Cerebral small vessel disease may worsen motor function, cognition, and mood in Parkinson’s disease. Parkinsonism Relat. Disord. 2021 83 86 92 10.1016/j.parkreldis.2020.12.025 33493785
69 Liu D. He X. Wu D. Zhang Q. Yang C. Liang F. He X. Dai G. Pei Z. Lan Y. Xu G. Continuous theta burst stimulation facilitates the clearance efficiency of the glymphatic pathway in a mouse model of sleep deprivation. Neurosci. Lett. 2017 653 189 194 10.1016/j.neulet.2017.05.064 28576566
70 Vasciaveo V. Iadarola A. Casile A. Dante D. Morello G. Minotta L. Tamagno E. Cicolin A. Guglielmotto M. Sleep fragmentation affects glymphatic system through the different expression of AQP4 in wild type and 5xFAD mouse models. Acta Neuropathol. Commun. 2023 11 1 16 10.1186/s40478-022-01498-2 36653878
71 Zhang R. Liu Y. Chen Y. Li Q. Marshall C. Wu T. Hu G. Xiao M. Aquaporin 4 deletion exacerbates brain impairments in a mouse model of chronic sleep disruption. CNS Neurosci. Ther. 2020 26 2 228 239 10.1111/cns.13194 31364823
72 Siow T.Y. Toh C.H. Hsu J.L. Liu G.H. Lee S.H. Chen N.H. Fu C.J. Castillo M. Fang J.T. Association of sleep, neuropsychological performance, and gray matter volume with glymphatic function in community-dwelling older adults. Neurology 2022 98 8 e829 e838 10.1212/WNL.0000000000013215 34906982
73 Wang X.X. Cao Q.C. Teng J.F. Wang R.F. Yang Z.T. Wang M.G. Cao Z.H. MRI-visible enlarged perivascular spaces: imaging marker to predict cognitive impairment in older chronic insomnia patients. Eur. Radiol. 2022 32 8 5446 5457 10.1007/s00330-022-08649-y 35286409
74 Rainey-Smith S.R. Mazzucchelli G.N. Villemagne V.L. Brown B.M. Porter T. Weinborn M. Bucks R.S. Milicic L. Sohrabi H.R. Taddei K. Ames D. Maruff P. Masters C.L. Rowe C.C. Salvado O. Martins R.N. Laws S.M. Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden. Transl. Psychiatry 2018 8 1 47 10.1038/s41398-018-0094-x 29479071
75 Piantino J. Schwartz D.L. Luther M. Newgard C. Silbert L. Raskind M. Pagulayan K. Kleinhans N. Iliff J. Peskind E. Link between mild traumatic brain injury, poor sleep, and magnetic resonance imaging: Visible perivascular spaces in veterans. J. Neurotrauma 2021 38 17 2391 2399 10.1089/neu.2020.7447 33599176
76 Shokri-Kojori E. Wang G.J. Wiers C.E. Demiral S.B. Guo M. Kim S.W. Lindgren E. Ramirez V. Zehra A. Freeman C. Miller G. Manza P. Srivastava T. De Santi S. Tomasi D. Benveniste H. Volkow N.D. β-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc. Natl. Acad. Sci. 2018 115 17 4483 4488 10.1073/pnas.1721694115 29632177
77 Eide P.K. Ringstad G. Cerebrospinal fluid egress to human parasagittal dura and the impact of sleep deprivation. Brain Res. 2021 1772 147669 10.1016/j.brainres.2021.147669 34587499
78 Chen W. Huang P. Zeng H. Lin J. Shi Z. Yao X. Cocaine-induced structural and functional impairments of the glymphatic pathway in mice. Brain Behav. Immun. 2020 88 97 104 10.1016/j.bbi.2020.04.057 32335199
79 Lundgaard I. Wang W. Eberhardt A. Vinitsky H.S. Reeves B.C. Peng S. Lou N. Hussain R. Nedergaard M. Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake on glymphatic function. Sci. Rep. 2018 8 1 2246 10.1038/s41598-018-20424-y 29396480
80 Liu Q. Yan L. Huang M. Zeng H. Satyanarayanan S.K. Shi Z. Chen D. Lu J.H. Pei Z. Yao X. Su H. Experimental alcoholism primes structural and functional impairment of the glymphatic pathway. Brain Behav. Immun. 2020 85 106 119 10.1016/j.bbi.2019.06.029 31247290
81 Li B. Zhang D. Verkhratsky A. Astrocytes in post-traumatic stress disorder. Neurosci. Bull. 2022 38 8 953 965 10.1007/s12264-022-00845-6 35349095
82 Van Praag H.M. Asnis G.M. Kahn R.S. Brown S.L. Korn M. Friedman J.M.H. Wetzler S. Monoamines and abnormal behaviour. A multi-aminergic perspective. Br. J. Psychiatry 1990 157 5 723 734 10.1192/bjp.157.5.723 1980627
83 Li C.T. Yang K.C. Lin W.C. Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: Evidence from clinical neuroimaging studies. Front. Psychiatry 2019 9 767 10.3389/fpsyt.2018.00767 30733690
84 Tay T.L. Béchade C. D’Andrea I. St-Pierre M.K. Henry M.S. Roumier A. Tremblay M.E. Microglia gone rogue: Impacts on psychiatric disorders across the lifespan. Front. Mol. Neurosci. 2018 10 421 10.3389/fnmol.2017.00421 29354029
85 Chong P.L.H. Garic D. Shen M.D. Lundgaard I. Schwichtenberg A.J. Sleep, cerebrospinal fluid, and the glymphatic system: A systematic review. Sleep Med. Rev. 2022 61 101572 10.1016/j.smrv.2021.101572 34902819
86 Mestre H. Hablitz L.M. Xavier A.L.R. Feng W. Zou W. Pu T. Monai H. Murlidharan G. Castellanos Rivera R.M. Simon M.J. Pike M.M. Plá V. Du T. Kress B.T. Wang X. Plog B.A. Thrane A.S. Lundgaard I. Abe Y. Yasui M. Thomas J.H. Xiao M. Hirase H. Asokan A. Iliff J.J. Nedergaard M. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. eLife 2018 7 e40070 10.7554/eLife.40070 30561329
87 Peng S. Liu J. Liang C. Yang L. Wang G. Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. Neurobiol. Dis. 2023 179 106035 10.1016/j.nbd.2023.106035 36796590
88 Taoka T. Ito R. Nakamichi R. Kamagata K. Sakai M. Kawai H. Nakane T. Abe T. Ichikawa K. Kikuta J. Aoki S. Naganawa S. Reproducibility of diffusion tensor image analysis along the perivascular space (DTI-ALPS) for evaluating interstitial fluid diffusivity and glymphatic function: CHanges in Alps index on Multiple conditiON acquIsition eXperiment (CHAMONIX) study. Jpn. J. Radiol. 2022 40 2 147 158 10.1007/s11604-021-01187-5 34390452
89 Walz R. Diaz A. Martins E.T. Rufino A. Amante L.N. Thais M.E. Quevedo J. Hohl A. Linhares M.N. Walz R. Psychiatric disorders and traumatic brain injury. Neuropsychiatr. Dis. Treat. 2008 4 4 797 816 10.2147/NDT.S2653 19043523
90 Bryant R.A. O’Donnell M.L. Creamer M. McFarlane A.C. Clark C.R. Silove D. The psychiatric sequelae of traumatic injury. Am. J. Psychiatry 2010 167 3 312 320 10.1176/appi.ajp.2009.09050617 20048022
91 Richmond-Rakerd L.S. D’Souza S. Milne B.J. Caspi A. Moffitt T.E. Longitudinal associations of mental disorders with dementia. JAMA Psychiat. 2022 79 4 333 340 10.1001/jamapsychiatry.2021.4377 35171209
92 Pancheri C. Verdolini N. Pacchiarotti I. Samalin L. Delle Chiaie R. Biondi M. Carvalho A.F. Valdes M. Ritter P. Vieta E. Murru A. A systematic review on sleep alterations anticipating the onset of bipolar disorder. Eur. Psychiatry 2019 58 45 53 10.1016/j.eurpsy.2019.02.003 30818134
93 Ritter P.S. Höfler M. Wittchen H.U. Lieb R. Bauer M. Pfennig A. Beesdo-Baum K. Disturbed sleep as risk factor for the subsequent onset of bipolar disorder: Data from a 10-year prospective-longitudinal study among adolescents and young adults. J. Psychiatr. Res. 2015 68 76 82 10.1016/j.jpsychires.2015.06.005 26228404
94 Bersani F.S. Iannitelli A. Pacitti F. Bersani G. Sleep and biorythm disturbances in schizophrenia, mood and anxiety disorders: A review. Riv. Psichiatr. 2012 47 5 365 375 10.1708/1175.13027 23160047
95 Yan T. Qiu Y. Yu X. Yang L. Glymphatic dysfunction: A bridge between sleep disturbance and mood disorders. Front. Psychiatry 2021 12 658340 10.3389/fpsyt.2021.658340 34025481
96 Jorm A.F. History of depression as a risk factor for dementia: An updated review. Aust. N. Z. J. Psychiatry 2001 35 6 776 781 10.1046/j.1440-1614.2001.00967.x 11990888
97 Medina A. Watson S.J. Bunney W. Jr Myers R.M. Schatzberg A. Barchas J. Akil H. Thompson R.C. Evidence for alterations of the glial syncytial function in major depressive disorder. J. Psychiatr. Res. 2016 72 15 21 10.1016/j.jpsychires.2015.10.010 26519765
98 Iwamoto K. Kakiuchi C. Bundo M. Ikeda K. Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol. Psychiatry 2004 9 4 406 416 10.1038/sj.mp.4001437 14743183
99 Althubaity N. Schubert J. Martins D. Yousaf T. Nettis M.A. Mondelli V. Pariante C. Harrison N.A. Bullmore E.T. Dima D. Turkheimer F.E. Veronese M. Choroid plexus enlargement is associated with neuroinflammation and reduction of blood brain barrier permeability in depression. Neuroimage Clin. 2022 33 102926 10.1016/j.nicl.2021.102926 34972034
100 Bernard R. Kerman I.A. Thompson R.C. Jones E.G. Bunney W.E. Barchas J.D. Schatzberg A.F. Myers R.M. Akil H. Watson S.J. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 2011 16 6 634 646 10.1038/mp.2010.44 20386568
101 Gos T. Schroeter M.L. Lessel W. Bernstein H.G. Dobrowolny H. Schiltz K. Bogerts B. Steiner J. S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: A postmortem study. J. Psychiatr. Res. 2013 47 11 1694 1699 10.1016/j.jpsychires.2013.07.005 23896207
102 Michel M. Fiebich B.L. Kuzior H. Meixensberger S. Berger B. Maier S. Nickel K. Runge K. Denzel D. Pankratz B. Schiele M.A. Domschke K. van Elst L.T. Endres D. Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression. Transl. Psychiatry 2021 11 1 308 10.1038/s41398-021-01423-6 34021122
103 Liao Y. Xie B. Zhang H. He Q. Guo L. Subramanieapillai M. Fan B. Lu C. McIntyre R.S. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl. Psychiatry 2019 9 1 190 10.1038/s41398-019-0515-5 31383846
104 Genel O. Pariante C.M. Borsini A. The role of AQP4 in the pathogenesis of depression, and possible related mechanisms. Brain Behav. Immun. 2021 98 366 377 10.1016/j.bbi.2021.08.232 34474133
105 Zhou X. Xiao Q. Xie L. Yang F. Wang L. Tu J. Astrocyte, a promising target for mood disorder interventions. Front. Mol. Neurosci. 2019 12 136 10.3389/fnmol.2019.00136 31231189
106 Kim Y.K. Jeon S.W. Neuroinflammation and the immune-kynurenine pathway in anxiety disorders. Curr. Neuropharmacol. 2018 16 5 574 582 10.2174/1570159X15666170913110426 28901278
107 Steiner J. Bielau H. Bernstein H-G. Bogerts B. Wunderlich M.T. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J. Neurol. Neurosurg. Psychiatry 2006 77 11 1284 1287 10.1136/jnnp.2006.093427 17043297
108 Tarasov V.V. Svistunov A.A. Chubarev V.N. Sologova S.S. Mukhortova P. Levushkin D. Somasundaram S.G. Kirkland C.E. Bachurin S.O. Aliev G. Alterations of astrocytes in the context of schizophrenic dementia. Front. Pharmacol. 2020 10 1612 10.3389/fphar.2019.01612 32116664
109 Hubbard J.A. Hsu M.S. Seldin M.M. Binder D.K. Expression of the astrocyte water channel aquaporin-4 in the mouse brain. ASN Neuro 2015 7 5 1759091415605486 10.1177/1759091415605486 26489685
110 Periyasamy P. Guo M.L. Buch S. Cocaine induces astrocytosis through ER stress-mediated activation of autophagy. Autophagy 2016 12 8 1310 1329 10.1080/15548627.2016.1183844 27337297
111 Miguel-Hidalgo J.J. Molecular neuropathology of astrocytes and oligodendrocytes in alcohol use disorders. Front. Mol. Neurosci. 2018 11 78 10.3389/fnmol.2018.00078 29615864
112 Shen M.D. Nordahl C.W. Li D.D. Lee A. Angkustsiri K. Emerson R.W. Rogers S.J. Ozonoff S. Amaral D.G. Extra-axial cerebrospinal fluid in high-risk and normal-risk children with autism aged 2-4 years: A case-control study. Lancet Psychiatry 2018 5 11 895 904 10.1016/S2215-0366(18)30294-3 30270033
113 Fatemi S.H. Folsom T.D. Reutiman T.J. Lee S. Expression of astrocytic markers aquaporin 4 and connexin 43 is altered in brains of subjects with autism. Synapse 2008 62 7 501 507 10.1002/syn.20519 18435417
114 Hendrickson R.C. Raskind M.A. Millard S.P. Sikkema C. Terry G.E. Pagulayan K.F. Li G. Peskind E.R. Evidence for altered brain reactivity to norepinephrine in Veterans with a history of traumatic stress. Neurobiol. Stress 2018 8 103 111 10.1016/j.ynstr.2018.03.001 29888305
115 Arent C.O. Valvassori S.S. Steckert A.V. Resende W.R. Dal-Pont G.C. Lopes-Borges J. Amboni R.T. Bianchini G. Quevedo J. The effects of n-acetylcysteine and/or deferoxamine on manic-like behavior and brain oxidative damage in mice submitted to the paradoxal sleep deprivation model of mania. J. Psychiatr. Res. 2015 65 71 79 10.1016/j.jpsychires.2015.04.011 25937502
116 Benedetti F. Fresi F. MacCioni P. Smeraldi E. Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav. Brain Res. 2008 187 2 221 227 10.1016/j.bbr.2007.09.012 17950929
117 da Rosa M.I. Simon C. Grande A.J. Barichello T. Oses J.P. Quevedo J. Serum S100B in manic bipolar disorder patients: Systematic review and meta-analysis. J. Affect. Disord. 2016 206 210 215 10.1016/j.jad.2016.07.030 27475892
118 Chen Y. Wang M. Su S. The structural and fuctional changes of glymphatic system in children with attention-deficit/hyperactivity disorder. Res. Square 2022 10.21203/rs.3.rs-1922962/v1
119 Abdolizadeh A. Carmona E.T. Ueno F. Nakajima S. Tarumi R. Tsugawa S. Honda S. Matsushita K. Caravaggio F. Song J. Chavez S. Noda Y. Uchida H. Remington G. Gerretsen P. Graff-Guerrero Ariel P548 Glymphatic system in schizophrenia: An H-MRS high-molecular-weight macromolecules study. Biolog. Psychiat. 2022 91 9 S310 S311 10.1016/j.biopsych.2022.02.785
